A researcher running a literature search on actin-binding peptides pulls forty papers under the heading “thymosin beta-4.” Reading the methods sections, she finds that some used the full-length protein, some used recombinant material, some used chemically synthesized protein, and several used a short synthetic peptide sold as TB-500. The abstracts rarely make the distinction. Before any comparison can be made, the papers have to be sorted by what molecule was actually in the tube.
This article sets out the structural difference between thymosin beta-4 and TB-500, why results for one cannot be assumed for the other, and what analytical evidence establishes which one you have.
Two molecules, not two names
| Thymosin beta-4 | TB-500 | |
|---|---|---|
| What it is | A 43-residue protein | A synthetic peptide corresponding to the actin-binding region of that protein |
| Defined sequence? | Yes | No single agreed sequence; a commercial designation |
| Contains LKKTET motif? | Yes, in its central region | Intended to, as the core of the fragment |
| Structure in solution | Intrinsically disordered on its own | Short linear peptide |
| Main identity check | Mass and sequence against the 43-residue protein | Mass against the specific sequence claimed |
The most practical point comes first. “TB-500” is not a chemical name. Material sold under it can differ in length and in whether the N-terminus is acetylated, so two vials labeled TB-500 from different sources may contain peptides of different mass. A purity percentage alone cannot tell you which fragment is present. Our overview of what TB-500 is gives the background on the name.
What the protein does at the molecular level
Thymosin beta-4 is best characterized as a G-actin sequestering protein. It binds monomeric actin and holds it in a form unavailable for polymerization into filaments, which places it at the center of much of the actin cytoskeleton literature. It is abundant inside many cell types.
The contact with actin depends on a six-residue motif, LKKTET, within the central part of the protein. A fragment that contains this motif retains measurable actin-binding activity in biochemical assays, which is the reason for making the fragment at all: a short sequence is far easier and cheaper to synthesize than a 43-residue protein while keeping the key recognition element.
An important structural subtlety: thymosin beta-4 has no stable fold by itself. It is intrinsically disordered in solution and adopts helical structure only on binding actin. A short fragment is therefore not “the folded domain” of the protein, because there is no folded domain to excise. What the fragment carries is a linear recognition motif, and the residues flanking it influence how well that motif is presented.
What does not carry over from protein to fragment
- Activities outside the motif. Anything the protein does through regions other than LKKTET is absent from a fragment that lacks those regions.
- Scale of sequestration. An abundant intracellular protein buffering the monomeric actin pool is a different situation from a short peptide added to an assay at a chosen concentration.
- Other derived peptides. A separately studied N-terminal tetrapeptide, Ac-SDKP, has its own literature. It is a different molecule from both the full protein and an actin-binding-region fragment.
- Physical behavior. A 43-residue, strongly acidic protein and a short fragment differ in charge, solubility, chromatographic retention and adsorption to surfaces.
The consequence for reading the literature is straightforward: a finding reported for the protein does not automatically apply to the fragment, and the reverse is equally true.
Sorting the literature: a checklist
- Identify the molecule from the methods section, not the title or abstract.
- Record the stated sequence and length. If a paper does not give them, note that the material is undefined.
- Convert concentrations to molar units. Because the protein is several times heavier than a short fragment, equal mass concentrations correspond to very different molar concentrations.
- Note the source of the material. Recombinant protein, synthetic protein and synthetic fragment carry different impurity profiles.
- Check for a comparator. A fragment result is most interpretable when the full-length protein was tested in parallel under the same conditions.
Assays that address actin binding directly
Where the question is whether a given peptide binds G-actin, cell-free biochemical assays give the most direct answer. Pyrene-actin polymerization assays follow the fluorescence increase that accompanies filament formation; a sequestering molecule slows polymerization or lowers the plateau. Sedimentation assays separate filamentous from monomeric actin by ultracentrifugation. Isothermal titration calorimetry and fluorescence anisotropy measure binding affinity. Circular dichroism can follow the disorder-to-helix transition on binding.
Establishing identity analytically
Because the name does not define a sequence, identity rests on comparing an observed mass with the mass calculated for a stated sequence, including any acetylation. Without a stated sequence, a mass has nothing to be checked against. Reverse-phase HPLC purity, with its method conditions stated, then describes how much of the eluting material is that species; deletion sequences one residue shorter can elute close to the main peak. See mass spectrometry and peptide identity for how mass confirmation works. Each Battle Born product is analyzed by independent reverse-phase HPLC and the result is published for that product. Where TB-500 appears in a multi-component product, the considerations in how multi-peptide blends are analyzed also apply.
Questions
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is a 43-residue protein. TB-500 is a commercial name for synthetic peptides based on its actin-binding region.
What is the LKKTET motif?
The six-residue sequence within thymosin beta-4 that makes the contact with monomeric actin.
Why do two TB-500 products differ in mass?
Because the name does not fix a sequence. Products can differ in length and in N-terminal acetylation.
Can results for the protein be applied to the fragment?
Not automatically. Each result applies to the molecule tested, and the methods section is where that is established.
Research use only. All products supplied by Battle Born Peptides are laboratory reference materials for in-vitro research and analytical use by qualified professionals. They are not drugs, foods, dietary supplements, cosmetics or medical devices; they are not approved by the FDA or any other regulator for use in humans or animals; and they are not intended to diagnose, treat, cure, mitigate or prevent any disease, or to affect the structure or any function of the body of humans or animals. Nothing in this article is preparation, handling or dosing guidance. See our full research-use terms.